MedPath

Bleeding risk after percutaneous endoscopic gastrostomy (PEG) with simultaneous treatment of aggressive antithrombotic-drug regimens

Not Applicable
Completed
Conditions
bleeding risk after PEG with and without antithrombotic drug regimes
risk of peritonitis after PEG with and without antithrombotic drug regimes
risk of infection after PEG with and without antithrombotic drug regimes
Surgery - Surgical techniques
Registration Number
ACTRN12608000194369
Lead Sponsor
Albert Ludwigs University Freiburg
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
1000
Inclusion Criteria

All 1057 patients referred between September 2001 and March 2007 to the endoscopic department of the Surgical Hospital at the University of Freiburg from in-house or external specialist departments (Neurology, Radiology, Clinic for Anesthesia, Cardiac Surgery and Orthodontic Surgery, ENT and Pediatrics and the International Medical Service -IMS) with the indication for percutaneous endoscopic gastrostomy (PEG) were enrolled according to predefined exclusion criteria

further criteria
cirrhosis
nicotinism
obesity
diabetes mellitus
coagulopathy
malignancy
neurological disorders
inflammatory disorders
radiation therapy
chemo therapy
alcoholism

ENT: Esopageal-Naso-Throat Hospital

Exclusion Criteria

The following exclusion criteria were defined: Patients in whom no standard pull-through” technique with or without prior Savary-Gilliard bouginage (SG-bouginage) in stenosis of the hypopharynx or esophagous was possible, patients in whom the PEG could not be placed without additional imaging (computer tomography), and patients in whom PEG placement had to be terminated prior to completion due to respiratory or other complications, or patients who died within the first 7 days.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath